Suzhou Shengdiya Biopharmaceuticals

Suzhou Shengdiya Biopharmaceuticals is a prominent Chinese biotechnology company and the core biologics subsidiary of Jiangsu Hengrui Pharmaceuticals. Based in the Suzhou Industrial Park, the company specializes in the discovery, development, and large-scale manufacturing of innovative therapeutic antibodies and proteins. Its portfolio includes several high-profile assets such as the PD-1 inhibitor camrelizumab and the PD-L1 inhibitor adebrelimab, both of which have achieved commercial success in China. The company operates advanced GMP-compliant facilities that support a robust pipeline of bispecific antibodies and antibody-drug conjugates (ADCs). As a vital component of Hengrui's global innovation strategy, Suzhou Shengdiya plays a critical role in transitioning the parent company from a generic-focused firm to a leading innovative biopharmaceutical player.